Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
Research Watch

Local Delivery of IFNα Has Antitumor Activity in Bladder Cancer

DOI: 10.1158/2159-8290.CD-RW2017-163 Published October 2017
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: Intravesical delivery of rAd-IFNα/Syn3 is safe and achieves durable responses in high-grade NMIBC.

  • Approach: An open-label phase II randomized trial evaluated the safety and activity of rAd-IFNα/Syn3.

  • Impact: rAd-IFNα/Syn3 warrants further investigation to treat BCG-refractory NMIBC tumors.


Embedded Image

Bacillus Calmette-Guerin (BCG) is the standard-of-care treatment for patients with high-grade non–muscle invasive bladder cancer (NMIBC) who are at high risk for recurrence and progression. However, 30% of patients with NMIBC exhibit no response to BCG, over half of patients relapse and progress after BCG treatment, and most patients are unwilling to undergo radical cystectomy. Shore and colleagues evaluated the activity and safety of intravesical delivery of recombinant adenovirus (rAd)-IFNα with Syn3 in a multicenter, open-label, parallel-arm, phase II study. A total of 40 patients with BCG-refractory or relapsed NMIBC were treated with either high-dose (19 patients) or low-dose (21 patients) rAd-IFNα/Syn3. The primary endpoint was relapse-free survival (RFS) at 12 months, and secondary endpoints included safety and tolerability of high- and low-dose rAd-IFNα/Syn3, levels of IFNα-2b in urine, and RFS at 3, 6, and 9 months. Objective responses were achieved in 7 patients (33.3%) in the low-dose group and 7 patients (36.8%) in the high-dose group, all of whom exhibited RFS at 12 months, and the median time to recurrence was 3.52 months for the low-dose group and 11.73 months for the high-dose group. Responses were durable; 8 of 11 patients remained disease-free for at least 15 months. Measurable levels of urine IFNα-2b were noted in month 1 in all patients after a single dose and in month 4 in patients who had received a second dose, but did not correlate with dose or response. rAd-IFNα/Syn3 was well tolerated, although 19 drug-related grade 3 events occurred in 9 patients (22%) and 10 severe adverse events occurred in 5 patients (12.5%), which were resolved with medical therapy. Taken together, the results of this phase II trial suggest that intravesical delivery of rAd-IFNα/Syn3 is safe and has durable antitumor activity in patients with BCG-refractory or relapsed NMIBC, supporting further investigation of rAd-IFNα/Syn3 alone or in combination with other therapies.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh, LI, Downs TM, et al. Intravesical rAD-IFNα/Syn3 for patients with high-grade, Bacillus Calmette-Guerin–refractory or relapsed non–muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol 2017 Aug 23 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2017 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 7 (10)
October 2017
Volume 7, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Local Delivery of IFNα Has Antitumor Activity in Bladder Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Local Delivery of IFNα Has Antitumor Activity in Bladder Cancer
Cancer Discov October 1 2017 (7) (10) 1059; DOI: 10.1158/2159-8290.CD-RW2017-163

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Local Delivery of IFNα Has Antitumor Activity in Bladder Cancer
Cancer Discov October 1 2017 (7) (10) 1059; DOI: 10.1158/2159-8290.CD-RW2017-163
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders
  • Pembrolizumab Monotherapy Is Active in Metastatic Prostate Cancer
  • MYC Superenhancer–Nuclear Pore Binding Increases MYC-Transcript Export
Show more Research Watch

Clinical Trials

  • Lazertinib Is Safe and Effective in Non–Small Cell Lung Cancer
  • Pegilodecakin Plus Anti–PD-1 Is Tolerable and Effective
  • Safety and Preliminary Evidence of Efficacy Shown for Rogaratinib
Show more Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement